Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer (Q57692990)

Raffaele Calogero

6

0 references

Mauro Papotti

9

Mauro Papotti

0 references

Giorgio Scagliotti

10

Giorgio V. Scagliotti

0 references

Marco Volante

1

Marco Volante

0 references

Silvia Novello

7

Silvia Novello

0 references

Ida Rapa

3

Ida Rapa

0 references

Paolo Ceppi

4

Paolo Ceppi

0 references

Susanna Cappia

5

Susanna Cappia

0 references

author name string

Piero Borasio

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

8

0 references

language of work or name

English

0 references

publication date

2007

0 references

published in

Cancer

0 references

volume

110

0 references

issue

6

0 references

page(s)

1321-1328

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

What is needed to satisfy the American College of Surgeons Commission on Cancer (COC) requirements for the pathologic reporting of cancer specimens?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

The biology of epidermal growth factor receptor in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021

Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22903

7 January 2021